1、 CEA CA125 Cyfra21-1 : (CEA) 125 (CA125) 19 (CYFRA21-1) : 2013 1 2016 12 40 , , 20 , 2 , , CEA CA125 Cyfra21-1 , : 65.0%, 30%, (P0.05) , 1.2 7 8 TNM IIIB IV , , , , , , , , , 1.3 1) IIIB IV ;2) 1 ( CT , 7 mm ) ;3) 3 ;4) ;5) , ;6) 1.4 ; ; ; ; 1.5 ; ; ; 1.6 , ( , :H08218520) 500 mg/m, d1 ( ( ) , H2007
2、3653) 30 mg/m, d13; ( , :H20030105) 1 000 mg/m, d1 d8 30 mg/m, d13; ( , :H20053001) 135mg/m, d1 30 mg/m, d13; 3 1 , 4 , , 1 1 : 10 g 10 g 15g 10 g 10 g 10 g 10 g 10 g, 1 /d, 400 m L 2 1.7 1) 2 ;2) 2 FACT-L ;3) 2 CEA CA125 Cyfra21-1 ;4) 2 1.8 1) 9 (CR) : ; (PR) : (PD) : 1/4, ; (SD) : 1/2 1/4; = (CR+P
3、R) / 2) (FACT-L) , 3) (CEA) 125 (CA125) 19 (CY-FRA21-1) , , 1.9 SPSS 20.0 , t , ; Wilcoxon , P0.05 2 2.1 2 65.0%, 30%, (P0.05) 1 1 2 (%) 2.2 2 FACT-L , (P0.05) 2 2 2 FACT-L ) 2.3 2 CEA CA125 CYFRA21-1 , (P0.05) 3 3 2 2.4 2 , , , (P0.05) 4 4 2 (%) 3 , , 10-11 , , , , , , 12 , , CEA , , , 13 CA125 , ,
4、 CEA CA125 14 CYFRA21-1 19 , , , 15 , CEA CA125 CY-FRA21-1 , , , CEA CA125 CYFRA21-1 , ; , CEA CA125 CYFRA21-1 , , , , , , , , , , , , , ( ) , , , , , , , 16 , , ; ; , , 17 , , , , , 18 , , , , , , , , , , , , , (P0.05) ; FACT-L , (P0.05) ; CEA CA125 CYFRA21-1 , (P0.05) , , , CEA CA125 CYFRA21-1 , 1
5、Deng X, Zheng Z, Lin B, et al.The efficacy and roles of combining temozolomide with whole brain radiotherapy in protection neurocognitive function and improvement quality of life of non-small-cell lung cancer patients with brain metastasesJ.BMC Cancer, 2017, 17 (1) :42. 2Okamura K, Takayama K, Izumi
6、 M, et al.Diagnostic value of CEAand CYFRA21-1 tumor markers in primary lung cancerJ.Lung Cancer, 2013, 80 (1) :45-49. 3Gong J, Zhang H, He L, Wang L, Wang J.Increased Expression of Long Non-Coding RNA BCAR4 Is Predictive of Poor Prognosis in Patients with Non-Small Cell Lung CancerJ.Tohoku J Exp Me
7、d, 2017, 241 (1) :29-34. 4Xiu P, Dong XF, Li XP, et al.Clusterin:Review of research progressand looking ahead to direction in hepatocellular carcinomaJ.World J Gastroenterol, 2015, 21 (27) :8262-8270. 5Govindan R, Ding L, Griffith M, et al.Genomic landscape ofnon-small cell lung cancer in smokers an
8、d never-smokersJ.Cell, 2012, 150 (6) :1121-1134. 6Liu MY, Li XQ, Gao TH, et al.Elevated HOTAIR expression associated with cisplatin resistance in non-small cell lung cancer patientsJ.J Thorac Dis, 2016, 8 (11) :3314-3322. 7 . M.2 . : , 1991:1-2. 8 . M. : , 2013:160-163. 9 . M. : , 2007:517. 10Koper
9、A, Zeef LA, Joseph L, et al.Whole Transcriptome Analysis of Pre-invasive and Invasive Early Squamous Lung Carcinoma in Archival Laser Microdissected SamplesJ.Respir Res, 2017, 18 (1) :12. 11Cheng Z, Shan F, Yang Y, et al.CT characteristics of non-small cell lung cancer with epidermal growth factor r
10、eceptor mutation:a systematic review and meta-analysisJ.BMC Med Imaging, 2017, 17 (1) :5. 12 , , , . CEA NSE CYFRA21-1 J. , 2016, 16 (10) :1908-1909. 13Pang L, Wang J, Jiang Y, et al.Decreased levels of serum cytokeratin19 fragment CYFRA21-1 predict objrctive response to chemotherapyin patients with
11、 non-small cell lung cancerJ.Exp Ther Med, 2013, 6 (2) :355-360. 14 , . CA153 CEA J. , 2012, 16 (11) :13-16. 15Lin XF, Wang XD, Sun DQ, et al.High serum CEA and CYFRA21-1levels after a two-cycle adjuvant chemotherapy for NSCLC:possiblepoor prognostic factorsJ.Cancer Biol Med, 2012, 9 (4) :270-273. 16 , , , . J. , 2016, 28 (3) :430. 17 , . J. , 2017, 32 (2) :685. 18 , , , . J. , 2014, 21 (6) :597-599.
